Chiesi Group is among "Sustainability Leaders 2021" companies in Italy

Chiesi Group, the largest international pharmaceutical Group certified B Corp, is among the top 150 Italian companies to be awarded "Leaders in Sustainability 2021".

The recognition comes from the survey conducted on approximately 1200 Italian-based corporations by Statista, a leading market research company specialized in ranking and analysis of business data, in collaboration with the Italian newspaper "Il Sole 24 Ore".

The analysis was conducted among companies active in Italy with the highest turnover in the country or listed on the Italian stock exchange. About 400 large Italian companies were then examined on the basis of the sustainability report (or equivalent document) as well as the 2019 or 2018 financial/annual report.

The subject of the research is the analysis of Corporate Social Responsibility (CSR) activities, considering three dimensions - environmental, social and economic – for a total of 35 indicators. These include CO₂ emissions and energy consumption (environment), percentage of women on the board of directors, number of employees with disabilities (social), financial stability and investment in research and development (economic).

The 150 companies with the best final score were awarded 'Sustainability Leaders 2021'. The list was published today on 'Il Sole 24 Ore' newspaper with a focus on the top 25 companies that received the highest score in the single areas, "environmental", "social" and "economic".

About Chiesi Group

Based in Parma, Italy, Chiesi is an international research-focused pharmaceuticals and healthcare group with over 85 years’ experience, operating in 30 countries with more than 6,000 employees (Chiesi Group). To achieve its mission of improving people’s quality of life by acting responsibly towards society and the environment, the Group researches, develops and markets innovative therapeutic solutions in its three focus areas: AIR (products and services that promote respiration, from new-born to adult populations), RARE (treatment for patients with rare and ultra-rare diseases) and CARE (products and services that support specialty care and consumer-facing self-care). The Group’s Research and Development centre is based in Parma and works alongside 6 other important research and development hubs in France, the U.S., Canada, China, the UK, and Sweden to pursue its pre-clinical, clinical, and regulatory programmes. In 2018 Chiesi has changed its legal status to a Benefit Corporation, according to the law in Italy, USA and, more recently, in France, by incorporating common benefit objectives into its bylaws, to generate value for its business, for the society and the environment. Since 2019, Chiesi has been the world’s largest B Corp certified pharmaceutical group. B Corps are global leaders convinced to leverage business as a force for good. Moreover, as a Benefit Corporation, Chiesi Farmaceutici S.p.A. is required by law to report annually in a transparent way about its progress in achieving the common benefits objectives it has set forward. The Group is committed to becoming carbon neutral by the end of 2035.